SEC Filing Summary: ChromaDex Corporation (8-K)
Business Context and Reporting Period
This Form 8-K reports the final voting results from the annual meeting of stockholders held on June 2, 2016. The registrant is ChromaDex Corporation, a Delaware corporation. Note: The input metadata references "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corporation.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses solely on corporate governance voting outcomes.
Material Changes and Voting Results
The following matters were submitted to a vote. Results reflect a 1-for-3 reverse stock split effected on April 13, 2016.
- Election of Directors: Six directors were elected to serve until the next annual meeting. All nominees received overwhelming support with "For" votes ranging from approximately 17.91 million to 17.92 million shares. "Withheld" votes ranged from approximately 76,684 to 83,350 shares. Broker non-votes totaled 10,638,326 shares for all nominees.
- Ratification of Auditors: The appointment of Marcum, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016, was ratified. The vote count was 28,402,404 "For," 8,874 "Against," and 13,518 "Abstain." Broker non-votes totaled 210,934 shares.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly reports the administrative results of the shareholder vote.
Key Facts for Investor Verification
- Verify the company name discrepancy between the metadata (Niagen Bioscience) and the filing (ChromaDex Corporation).
- Confirm the impact of the 1-for-3 reverse stock split on share counts and voting thresholds.
- Review the definitive proxy statement filed on April 12, 2016, and the addendum filed on May 12, 2016, for detailed background on the director nominees and auditor appointment.
- Note the significant number of broker non-votes (over 10 million shares) regarding the director elections.